Showing results (301-310 of 352) with videos related to
Sort By:
Pageof 36
JAAD International|February 3, 2026
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)Kristina Callis Duffin, Christopher E M Griffiths, Matthias Hoffmann, et al.Journal of the American Academy of Dermatology|April 22, 2008
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologicsAlan Menter, Alice Gottlieb, Steven R Feldman, et al.Journal of the American Academy of Dermatology|January 16, 2018
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis FoundationScott M Whitlock, Clinton W Enos, April W Armstrong, et al.The Journal of Dermatology|June 2, 2026
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic DiseaseLuis Puig, Tsen-Fang Tsai, Enrique R Soriano, et al.Journal of the American Academy of Dermatology|April 22, 2008
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologicsAlice Gottlieb, Neil J Korman, Kenneth B Gordon, et al.American Journal of Clinical Dermatology|August 7, 2026
Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical TrialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.Dermatology and Therapy|January 22, 2025
Long-Term Safety of Ixekizumab Treatment in Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: a Post Hoc Analysis of Cerebro-Cardiovascular EventsMark Lebwohl, Atul Deodhar, Sergio Schwartzman, et al.Journal of the American Academy of Dermatology|November 28, 2016
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated dataBruce Strober, Craig Leonardi, Kim A Papp, et al.Journal of the American Academy of Dermatology|May 22, 2016
Clinical meaningfulness of complete skin clearance in psoriasisBruce Strober, Kim A Papp, Mark Lebwohl, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.Pageof 36